Symphogen A/S - Product Pipeline Review - 2016

Published: Dec, 2016 | Pages: 38 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Symphogen A/S - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Symphogen A/S - Product Pipeline Review - 2016', provides an overview of the Symphogen A/S's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Symphogen A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Symphogen A/S
- The report provides overview of Symphogen A/S including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Symphogen A/S's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Symphogen A/S's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Symphogen A/S's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Symphogen A/S
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Symphogen A/S's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Symphogen A/S Snapshot 6
Symphogen A/S Overview 6
Key Facts 6
Symphogen A/S - Research and Development Overview 7
Key Therapeutic Areas 7
Symphogen A/S - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Symphogen A/S - Pipeline Products Glance 12
Symphogen A/S - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Symphogen A/S - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Symphogen A/S - Drug Profiles 16
futuximab + modotuximab - Drug Profile 16
Product Description 16
Mechanism Of Action 16
R&D Progress 16
Monoclonal Antibodies 1 for Oncology - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
Monoclonal Antibodies for Oncology - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
Monoclonal Antibody to Antagonize PD1 for Oncology - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
Monoclonal Antibody to Inhibit LAG-3 for Oncology - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
Monoclonal Antibody to Inhibit TIM-3 for Oncology - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Sym-013 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
SYM-015 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Symphogen A/S - Pipeline Analysis 28
Symphogen A/S - Pipeline Products by Target 28
Symphogen A/S - Pipeline Products by Route of Administration 29
Symphogen A/S - Pipeline Products by Molecule Type 30
Symphogen A/S - Pipeline Products by Mechanism of Action 31
Symphogen A/S - Dormant Projects 32
Symphogen A/S - Discontinued Pipeline Products 33
Discontinued Pipeline Product Profiles 33
rozrolimupab 33
Symphogen A/S - Company Statement 34
Symphogen A/S - Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36

Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 37
Disclaimer 38

List of Tables

Symphogen A/S, Key Facts 6
Symphogen A/S - Pipeline by Indication, 2016 8
Symphogen A/S - Pipeline by Stage of Development, 2016 9
Symphogen A/S - Monotherapy Products in Pipeline, 2016 10
Symphogen A/S - Combination Treatment Modalities in Pipeline, 2016 11
Symphogen A/S - Phase II, 2016 12
Symphogen A/S - Phase I, 2016 13
Symphogen A/S - Preclinical, 2016 14
Symphogen A/S - Discovery, 2016 15
Symphogen A/S - Pipeline by Target, 2016 28
Symphogen A/S - Pipeline by Route of Administration, 2016 29
Symphogen A/S - Pipeline by Molecule Type, 2016 30
Symphogen A/S - Pipeline Products by Mechanism of Action, 2016 31
Symphogen A/S - Dormant Developmental Projects,2016 32
Symphogen A/S - Discontinued Pipeline Products, 2016 33
Symphogen A/S, Subsidiaries 36